Skip to content
Bamboo Works
Search
Register / Sign in
MSCI China | MSCI China Small-Cap | Hang Seng Index | Hang Seng China Enterprise
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
  • Fast News
  • Expert Corner
  • Audio/Video
  • China ESG
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us
  • Eng
  • 简中
  • 繁中
Menu
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
  • Fast News
  • Expert Corner
  • Audio/Video
  • China ESG
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us

BeiGene Ltd.

BeiGene celebrates profit milestone

BeiGene celebrates profit milestone on soaring drug sales

Buoyed by U.S. demand for its blockbuster cancer drug, the Chinese biopharma firm has delivered its first quarterly profit on a GAAP basis Key Takeaways: Global sales of the company’s…
May 15, 2025
6160.HK ONC.US 688325.SHG

FAST NEWS: BeiGene Loss Narrows on Brisk Sales for Core Products

The latest: Cancer drug maker BeiGene Ltd. (BGNE.US; 6160.HK; 668235.SH) announced Monday its revenue rose 20.4% last year to $1.42 billion, thanks to big increases from its two core products,…
February 28, 2023
6160.HK

FAST NEWS: I-Mab to Move Ahead With Dual Listing in Hong Kong

The latest: U.S.-listed cancer drug developer I-Mab (IMAB.US) announced its board has approved a motion to pursue a listing on the Hong Kong Stock Exchange. The board also authorized the company's…
December 8, 2021

Pandemic Accelerates China’s Drive Into mRNA Treatments

Messenger RNA-based technology that is highly effective in preventing Covid-19 can also be used for treatment of other diseases Key points: High efficacy rates in preventing Covid-19 spark rush by…
June 18, 2021

Recent Articles

BeiGene celebrates profit milestone
May 15, 2025

BeiGene celebrates profit milestone on soaring drug sales

6160.HK ONC.US 688325.SHG
February 28, 2023

FAST NEWS: BeiGene Loss Narrows on Brisk Sales for Core Products

6160.HK
December 8, 2021

FAST NEWS: I-Mab to Move Ahead With Dual Listing in Hong Kong

June 18, 2021

Pandemic Accelerates China’s Drive Into mRNA Treatments

RELATED ARTICLES

  1. BeiGene
    January 24, 2025
    BeiGene heads for profit milestone after hemorrhaging cash
    6160.HK ONC.US 688235.SHG
  2. March 6, 2025
    Earnings blow for CSPC Pharma as the state drives a hard bargain
    1093.HK
  3. May 8, 2025
    RNA drug developer Ribo Life targets fresh funding channel
  4. January 9, 2025
    Cancer drug maker Genfleet joins Hong Kong IPO influx
  5. April 10, 2025
    Investors cheer Akeso’s revenue milestone, even as it returns to the red
    9926.HK
  6. March 20, 2025
    A blockbuster cancer drug? TYK’s claims go under the microscope
    2410.HK
  7. December 13, 2024
    Innogen Pharma jostles for a slice of the weight-loss market
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva

China stock insights and analysis for global investors: Bamboo Works unlocks investment opportunities in Chinese companies listed in the U.S. & Hong Kong.

  • About Us
  • Fast News
  • Audio/Video
  • Expert Corner
  • China ESG
Facebook Twitter Linkedin Weixin Weibo Youtube

Categories

  • New Energy
  • IPO
  • AI/Infrastructure/Resources
  • Education
  • Finance
  • Social Media/Entertainment
  • Consumer
  • Ecommerce
  • Healthcare/biotech
  • Property

Newsletter

Discover hidden China stock gems in our weekly newsletter
Copyright © 2021 - 2025 Bamboo Works. All rights reserved.